Stocks Pressured by Escalation of Trade Tensions
Stock indexes on Friday retreated on the escalation of trade tensions as President Trump ramped up his threats to impose higher tariffs, sparking a risk-off environment in asset markets. Late Thursday, President Trump said a 35% tariff on some Canadian products would take effect on August 1, up from the current 25%. The new Canadian tariffs would not apply to goods traded within the rules of the US-Mexico-Canada Trade Agreement, and a lower 10% tariff would be kept on some energy-related imports. He also said he plans to impose blanket tariffs of 15% or 20% on most US trade partners.
Why Wall Street Is Betting on Alibaba Stock Gaining 70% From Here
From Penny Stock to AI Powerhouse, Is SOUN Stock a Buy Now?
The Saturday Spread: Leveraging Applied Game Theory to Find Probabilistically Attractive Trades
Stop Missing Market Moves: Get the FREE Barchart Brief – your midday dose of stock movers, trending sectors, and actionable trade ideas, delivered right to your inbox. Sign Up Now!
Stocks were also undercut by Friday's +7 bp rise in the 10-year T-note yield. T-note yields rose on concern that President Trump's threats to impose higher tariffs on Canada and other US trading partners will lead to higher US inflation that could prevent the Fed from cutting interest rates.
The price of Bitcoin (^BTSUSD) on Friday rallied by more than +3% and posted a new record high. Bitcoin has rallied more than +9% this week after the US House Committee on Financial Services announced on Tuesday that the week of July 14 will be 'Crypto Week.' The US House Committee on Ways and Means has planned an oversight subcommittee hearing on July 16 entitled, 'Making America the Crypto Capital of the World,' which may lead to more crypto-friendly regulations.
Stocks have been undercut as President Trump vowed to push forward with his aggressive tariff regime, stressing he would not offer additional extensions on country-specific tariffs set to take effect on August 1. Earlier this week, Mr. Trump imposed a 50% tariff on copper imports that will include semi-finished goods, and said that drug companies could face tariffs as high as 200% on imports if they don't relocate production to the US within the next year. In addition, despite stating that the US was close to a trade deal with India, Mr. Trump said he would still impose a 10% tariff on India's goods for their participation in BRICS, a group of developing nations he claimed were 'set up to hurt' the US.
Another hurdle for stocks is the upcoming earnings season, which begins in earnest next week. Bloomberg Intelligence data show that the consensus for Q2 earnings of S&P 500 companies is for a rise of +2.8% year-over-year, the smallest increase in two years. Also, only six of the eleven S&P 500 sectors are projected to post an increase in earnings, the fewest since Q1 of 2023, according to Yardeni Research.
Federal funds futures prices are discounting the chances at 7% for a -25 bp rate cut at the July 29-30 FOMC meeting.
Overseas stock markets Friday were mixed. The Euro Stoxx 50 fell -1.01%. China's Shanghai Composite climbed to a 9-month high and closed up +0.01%. Japan's Nikkei Stock 225 fell to a 1-week low and closed down -0.19%.
Interest Rates
September 10-year T-notes (ZNU25) on Friday fell by -15 ticks. The 10-year T-note yield rose by +7 bp to 4.419%. T-note prices fell on President Trump's threats to impose higher tariffs on Canada and other US trading partners, which fueled concern about higher US inflation that could prevent the Fed from cutting interest rates. T-note prices were also undercut after the 10-year German bund yield rose to a 3.25-month high.
European government bond yields moved higher. The 10-year German bund yield rose to a 3.25-month high of 2.734% and ended the day up +2.0 bp at 2.725%. The 10-year UK gilt yield rose +2.6 bp to 4.622%.
UK May manufacturing production fell -1.0% m/m, weaker than expectations of -0.1% m/m and the biggest decline in 10 months.
ECB Executive Board member Isabel Schnabel said, 'The bar for another ECB interest rate cut is very high, and there would only be a case for another rate cut if we saw signs of a material deviation of inflation from our target over the medium term. And at the moment, I see no signs of that.'
Swaps are discounting the chances at 1% for a -25 bp rate cut by the ECB at the July 24 policy meeting.
US Stock Movers
The Magnificent Seven stocks held up fairly well on Friday despite the losses in the main indexes, with only Apple (AAPL) and Meta Platforms (META) showing losses. Alphabet (GOOG), Amazon (AMZN), and Tesla (TSLA) all closed up by more than +1%.
Nvidia (NVDA) rose +0.5% after CEO Huang met President Trump at the White House, ahead of Huang's trip to China.
Some cryptocurrency stocks rallied as the price of Bitcoin (^BTCUSD) rose more than +3% to a new record high. MicroStrategy (MSTR) rose more than +3% to lead gainers in the Nasdaq 100.
Drone-related companies climbed after US Defense Secretary Pete Hegseth issued orders to ramp up production and deployment of drones. Red Cat Holdings (RCAT) rallied more than +25%, Kratos Defense & Security Solutions (KTOS) rallied more than +11%, and AeroVironment (AVAV) rallied more than +10%.
Airline stocks on Friday moved lower, giving back some of Thursday's sharp gains that were driven by positive guidance news from Delta. American Airlines Group (AAL) fell more than -5%, United Airlines Holdings (UAL) fell more than -4%, and Alaska Air Group (ALK) fell more than -3%. Delta Air Lines (DAL) fell -0.25% after Thursday's surge of nearly +12%.
Capricor Therapeutics (CAPR) plunged -33% after the FDA declined to approve the company's treatment candidate aimed at treating a disease of the heart muscle associated with Duchenne muscular dystrophy.
Civista Bancshares (CIVB) fell more than -13% after announcing the pricing of an underwritten public offering of 3.29 million shares of common stock at a price of $21.25 per share, below Thursday's closing price of $24.82.
Oscar Health (OSCR) fell more than -7% after Wells Fargo Securities downgraded the stock to underweight from equal weight with a price target of $10.
Albemarle (ALB) fell more than -4% after UBS downgraded the stock to sell from neutral with a price target of $57.
Expeditors International of Washington (EXPD) fell nearly -3% after Bank of America Global Research downgraded the stock to underperform.
Northern Trust Corp (NTRS) fell -0.6% after Keefe, Bruyette & Woods downgraded the stock to underperform from market perform with a price target of $120.
Levy Strauss & Co (LEVI) rose more than +11% after reporting Q2 net revenue of $1.45 billion, stronger than the consensus of $1.37 billion, and raising guidance on its full-year net revenue forecast to up +1% to +2% from a previous forecast of down -1% to -2%.
Performance Food Group (PFGC) rose by more than +4% on reports that the company has attracted takeover interest from US Foods Holding Corp.
Visteon Corp (VC) rose by more than +2% after Goldman Sachs upgraded the stock to buy from neutral with a price target of $120.
Earnings Reports (7/14/2025)
Equity Bancshares Inc (EQBK), Fastenal Co (FAST), FB Financial Corp (FBK), Immersion Corp (IMMR), Kestra Medical Technologies Ltd (KMTS), Rezolve AI PLC (RZLV), Simulations Plus Inc (SLP).
On the date of publication, Rich Asplund did not have (either directly or indirectly) positions in any of the securities mentioned in this article. All information and data in this article is solely for informational purposes. This article was originally published on Barchart.com
Hashtags

Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Yahoo
11 minutes ago
- Yahoo
OpenAI's Wallet Just Got Heavier -- Because Meta's Been Poaching
OpenAI isn't just building cutting-edge AI anymore; it's now fighting a full-blown talent war and it's using stock options as its shield. The company known worldwide for ChatGPT has seen its stock-based compensation jump more than five times over the past year; that's not a typo. In total, OpenAI handed out $4.4 billion in equity; that figure was 119% of its entire revenue for the same period. Yes it's now literally paying out more in stock than it's earning. Warning! GuruFocus has detected 6 Warning Sign with META. And the trigger? Meta (META, Financials) which has reportedly lured away at least nine researchers from OpenAI's AI team including some working on foundational models. These exits weren't minor; they cut deep. OpenAI had hoped this stock-based spending spree would cool off by 2025 projecting equity payouts to drop to 45% of revenue, and then under 10% by the end of the decade. But that was before Meta started raiding its brain trust. Now, those assumptions are out the window. According to internal chatter, Chief Research Officer Mark Chen believes the company might have to sweeten its equity offers even more; because when your biggest assets walk out the door, the only thing left to do is open it wider with better incentives. This isn't just about keeping salaries competitive; it's about survival. The AI space is getting fiercer by the week; and even with Microsoft in its corner, OpenAI can't afford to lose talent to rivals. Equity compensation isn't a perk anymore; it's a weapon. And OpenAI is loading up. This article first appeared on GuruFocus. Error in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data
Yahoo
11 minutes ago
- Yahoo
US High Growth Tech Stocks Leading The Market
The United States market remained flat over the last week, but it has risen 13% over the past 12 months with earnings forecasted to grow by 15% annually. In this context, identifying high growth tech stocks that align with these positive earnings projections can be key to capitalizing on potential future opportunities in the sector. Name Revenue Growth Earnings Growth Growth Rating Super Micro Computer 24.71% 39.09% ★★★★★★ Circle Internet Group 30.78% 60.64% ★★★★★★ Ardelyx 21.16% 61.58% ★★★★★★ Mereo BioPharma Group 50.84% 58.22% ★★★★★★ TG Therapeutics 26.46% 38.75% ★★★★★★ AVITA Medical 27.42% 61.04% ★★★★★★ Alnylam Pharmaceuticals 23.86% 59.49% ★★★★★★ Alkami Technology 20.53% 76.67% ★★★★★★ Ascendis Pharma 35.07% 59.83% ★★★★★★ Lumentum Holdings 23.14% 103.97% ★★★★★★ Click here to see the full list of 228 stocks from our US High Growth Tech and AI Stocks screener. We're going to check out a few of the best picks from our screener tool. Simply Wall St Growth Rating: ★★★★★☆ Overview: KalVista Pharmaceuticals, Inc. is a clinical stage pharmaceutical company focused on the discovery, development, and commercialization of drug therapies for diseases with unmet needs, with a market cap of $748.72 million. Operations: KalVista Pharmaceuticals specializes in developing drug therapies, particularly inhibitors, targeting diseases with unmet needs. The company operates as a clinical stage entity without reported revenue segments, focusing on advancing its pipeline through discovery and development phases. KalVista Pharmaceuticals, recently approved by the FDA for its novel treatment EKTERLY®, is poised to revolutionize care for hereditary angioedema (HAE) with the first oral on-demand option. This approval follows a robust KONFIDENT trial, which demonstrated EKTERLY®'s efficacy in significantly reducing symptom severity and attack resolution times compared to placebo. With an annual revenue growth forecast at 49.7% and earnings expected to surge by 54.67%, KalVista's strategic focus on R&D has positioned it well within the high-growth biotech sector, despite current unprofitability. The company's recent distribution agreement with Pendopharm® marks a significant step towards expanding its market reach in Canada, enhancing its growth trajectory amidst a competitive landscape. Delve into the full analysis health report here for a deeper understanding of KalVista Pharmaceuticals. Gain insights into KalVista Pharmaceuticals' past trends and performance with our Past report. Simply Wall St Growth Rating: ★★★★★☆ Overview: Hut 8 Corp. is a vertically integrated operator of energy infrastructure and Bitcoin mining in North America with a market capitalization of $2.44 billion. Operations: Hut 8 Corp. generates revenue through its power segment, contributing $51.04 million, and digital infrastructure, adding $20.99 million. The company is involved in energy infrastructure and Bitcoin mining operations across North America. Amidst a challenging landscape, Hut 8's Vega facility marks a significant stride in Bitcoin mining technology. With an innovative liquid cooling system, the facility optimizes thermal efficiency and operational reliability, supporting compute densities up to 180 kilowatts per rack—a notable advancement over traditional air-cooled systems. Despite recent drops from various Russell indexes and a substantial net loss reported in Q1 2025, Hut 8's amended credit agreement with Coinbase suggests strategic financial maneuvering to bolster its growth trajectory. This move could potentially stabilize the company amidst volatile market conditions and pave the way for leveraging emerging high-performance computing workloads. Take a closer look at Hut 8's potential here in our health report. Gain insights into Hut 8's historical performance by reviewing our past performance report. Simply Wall St Growth Rating: ★★★★☆☆ Overview: Altice USA, Inc. operates as a provider of broadband communications and video services under the Optimum brand across the United States, Canada, Puerto Rico, and the Virgin Islands with a market cap of approximately $1.04 billion. Operations: Altice USA, operating under the Optimum brand, generates revenue primarily from its cable segment, which amounts to approximately $8.86 billion. The company focuses on delivering broadband communications and video services across multiple regions. Altice USA's recent inclusion in multiple Russell indexes underscores its potential in the tech sector, despite a forecasted annual revenue decline of 2%. This juxtaposition highlights the company's strategic positioning and investor interest. With earnings expected to grow by 66.76% annually, Altice is navigating its financial challenges, evidenced by a significant net loss of $75.68 million in Q1 2025. These developments suggest a complex but possibly rewarding future as it aims for profitability amidst operational adjustments and market recognition. Click here and access our complete health analysis report to understand the dynamics of Altice USA. Evaluate Altice USA's historical performance by accessing our past performance report. Discover the full array of 228 US High Growth Tech and AI Stocks right here. Invested in any of these stocks? Simplify your portfolio management with Simply Wall St and stay ahead with our alerts for any critical updates on your stocks. Streamline your investment strategy with Simply Wall St's app for free and benefit from extensive research on stocks across all corners of the world. Explore high-performing small cap companies that haven't yet garnered significant analyst attention. Fuel your portfolio with companies showing strong growth potential, backed by optimistic outlooks both from analysts and management. Find companies with promising cash flow potential yet trading below their fair value. This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned. Companies discussed in this article include KALV HUT and ATUS. Have feedback on this article? Concerned about the content? with us directly. Alternatively, email editorial-team@ Error in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data


Wall Street Journal
11 minutes ago
- Wall Street Journal
Gold Advances Amid Rising Trade Tensions
2340 GMT — Gold advances in the early Asian session amid rising trade tensions that typically enhance the safe-haven appeal of the precious metal. The U.S. will impose a 30% tariff on goods from the EU and Mexico effective Aug. 1, President Trump said in letters to them, posted on Truth Social on Saturday. The tariffs 'represent escalations that have undermined hopes for comprehensive agreements to end the broader global trade conflict,' Samer Hasn says in an email. 'These developments reinforce the likelihood of actual tariffs being imposed by August 1, reviving concerns over their potential implications for the U.S. economy,' the senior market analyst adds. Spot gold is 0.4% higher at $3,367.16/oz. (